rs7623808
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_032505.3(KBTBD8):c.*2480G>T variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.171 in 152,486 control chromosomes in the GnomAD database, including 2,468 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.17 ( 2462 hom., cov: 32)
Exomes 𝑓: 0.16 ( 6 hom. )
Consequence
KBTBD8
NM_032505.3 3_prime_UTR
NM_032505.3 3_prime_UTR
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.759
Publications
5 publications found
Genes affected
KBTBD8 (HGNC:30691): (kelch repeat and BTB domain containing 8) Involved in neural crest cell development; neural crest formation; and protein monoubiquitination. Part of Cul3-RING ubiquitin ligase complex. [provided by Alliance of Genome Resources, Apr 2022]
KBTBD8 Gene-Disease associations (from GenCC):
- Tourette syndromeInheritance: Unknown Classification: NO_KNOWN Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.64).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.248 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.171 AC: 26026AN: 151936Hom.: 2451 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
26026
AN:
151936
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.164 AC: 71AN: 432Hom.: 6 Cov.: 0 AF XY: 0.158 AC XY: 41AN XY: 260 show subpopulations
GnomAD4 exome
AF:
AC:
71
AN:
432
Hom.:
Cov.:
0
AF XY:
AC XY:
41
AN XY:
260
show subpopulations
African (AFR)
AC:
0
AN:
0
American (AMR)
AC:
0
AN:
0
Ashkenazi Jewish (ASJ)
AC:
0
AN:
0
East Asian (EAS)
AC:
0
AN:
0
South Asian (SAS)
AC:
0
AN:
0
European-Finnish (FIN)
AF:
AC:
69
AN:
426
Middle Eastern (MID)
AC:
0
AN:
0
European-Non Finnish (NFE)
AF:
AC:
0
AN:
2
Other (OTH)
AF:
AC:
2
AN:
4
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.489
Heterozygous variant carriers
0
5
10
16
21
26
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.171 AC: 26070AN: 152054Hom.: 2462 Cov.: 32 AF XY: 0.170 AC XY: 12652AN XY: 74332 show subpopulations
GnomAD4 genome
AF:
AC:
26070
AN:
152054
Hom.:
Cov.:
32
AF XY:
AC XY:
12652
AN XY:
74332
show subpopulations
African (AFR)
AF:
AC:
10456
AN:
41456
American (AMR)
AF:
AC:
3047
AN:
15276
Ashkenazi Jewish (ASJ)
AF:
AC:
422
AN:
3468
East Asian (EAS)
AF:
AC:
143
AN:
5184
South Asian (SAS)
AF:
AC:
549
AN:
4816
European-Finnish (FIN)
AF:
AC:
1801
AN:
10576
Middle Eastern (MID)
AF:
AC:
28
AN:
294
European-Non Finnish (NFE)
AF:
AC:
9224
AN:
67964
Other (OTH)
AF:
AC:
352
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1087
2175
3262
4350
5437
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
264
528
792
1056
1320
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
291
AN:
3476
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.